[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,476,854
  • Shares Outstanding, K 23,104
  • Annual Sales, $ 958,400 K
  • Annual Income, $ -288,280 K
  • EBIT $ -323 M
  • EBITDA $ -316 M
  • 60-Month Beta -1.01
  • Price/Sales 12.87
  • Price/Cash Flow N/A
  • Price/Book 23.55

Options Overview Details

View History
  • Implied Volatility 44.01% (-1.48%)
  • Historical Volatility 50.35%
  • IV Percentile 12%
  • IV Rank 20.18%
  • IV High 73.99% on 11/03/25
  • IV Low 36.43% on 05/06/26
  • Expected Move (DTE 17) 42.80 (7.94%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 170
  • Volume Avg (30-Day) 312
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 12,713
  • Open Int (30-Day) 13,329
  • Expected Range 495.91 to 581.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.00
  • Number of Estimates 6
  • High Estimate $-0.10
  • Low Estimate $-2.00
  • Prior Year $-5.08
  • Growth Rate Est. (year over year) +80.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
461.25 +16.79%
on 08/03/26
550.33 -2.11%
on 08/26/26
+71.39 (+15.28%)
since 07/31/26
3-Month
445.20 +21.00%
on 06/03/26
569.44 -5.40%
on 07/09/26
+57.48 (+11.94%)
since 06/01/26
52-Week
393.61 +36.87%
on 10/29/25
615.00 -12.40%
on 12/24/25
+100.86 (+23.04%)
since 08/29/25

Most Recent Stories

More News
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 538.71 (-0.24%)
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in...

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46 th Annual Growth Conference...

MDGL : 538.71 (-0.24%)
Madrigal: Q2 Earnings Snapshot

Madrigal: Q2 Earnings Snapshot

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more...

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates

Second-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000...

MDGL : 538.71 (-0.24%)
Madrigal's Rezdiffra Revenue Momentum May Already Be Reflecting a Best-Case Scenario That Hasn't Arrived

Barchart Research What to Expect from MDGL Earnings MDGL Generated July 29, 2026 Current Price $546.88 EPS Estimate $$-2.55 Consensus Rating Strong Buy Average Move 10.51% Madrigal's Rezdiffra Revenue...

MDGL : 538.71 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 563.27
2nd Resistance Point 555.93
1st Resistance Point 547.32
Last Price 538.71
1st Support Level 531.38
2nd Support Level 524.04
3rd Support Level 515.43

See More

52-Week High 615.00
Last Price 538.71
Fibonacci 61.8% 530.43
Fibonacci 50% 504.30
Fibonacci 38.2% 478.18
52-Week Low 393.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.